Genascence Announces Six-Month Results From Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
UF startup Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001.
UF Researchers To Study Pain, With Help From Horses
UF researchers are collaborating on a $5.4 million NIH grant to study osteoarthritis pain and progression in humans and horses, leveraging their unique expertise.
Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients With Osteoarthritis (OA) of the Knee
UF Startup Genascence Corporation announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for GNSC-001, a potential first-in-class gene therapy for the treatment of patients with osteoarthritis (OA) of the knee.
Novel Target Discovered for Potentially Treating and Preventing Osteoarthritis
Scientists at UF Scripps Biomedical Research have described a specific protein that manages activities within chondrocytes, a critical cell type that maintains healthy cartilage in joints. As people age and stress their joints, their chondrocytes begin to fail. The UF Scripps team found that activating a specific protein in these cells called RORβ (beta) could restore multiple factors needed for smooth joints to healthier levels, helping to control inflammation.
